Leidos awarded prime contract to support helicopters and fixed-wing aircraft for Afghanistan Air Force

October 24, 2017 Media Relations

(Reston, Va.) October 24, 2017 – Leidos (NYSE: LDOS), a FORTUNE 500® science and technology company, was awarded a prime contract by the U.S. Army to support the Afghanistan Air Force (AAF) and Special Mission Wing (SMW) helicopter and fixed-wing fleets. Work will be performed in Kabul, Afghanistan, with an estimated completion date of May 31, 2020 at a total potential contract value up to $728 million.

Through the Afghanistan Contractor Logistics Support contract, Leidos will deliver all flight operations, maintenance, and logistics, and will provide mentoring for the AAF and SMW to operate and maintain aircraft. Leidos has applied its logistics and operations expertise in Afghanistan to support the AAF and SMW, while also providing aviation services to the customer.

 “This award reflects our commitment to the customer’s mission,” said Leidos Defense & Intelligence President Tim Reardon. “We look forward to continuing to provide superior flight operations, maintenance, logistics, and mentoring expertise.”

About Leidos

Leidos is a FORTUNE 500® science and technology solutions and services leader working to solve the world’s toughest challenges in the defense, intelligence, homeland security, civil, and health markets.  The company’s 32,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $7.04 billion for the fiscal year ended December 30, 2016.  For more information, visit www.Leidos.com.

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company’s Annual Report on Form 10-K for the period ended December 30, 2016, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.


Image credit: Taken from NATO and used under license CC BY-SA 4.0

About

Media Contacts:

Melissa Koskovich, SVP Communications, (571) 526-6850, melissa.l.koskovich@leidos.com

Jason Kello, Director - Media Relations, jason.kello@leidos.com

More Content by Media Relations
Previous Article
Leidos announces Ethan Dmitrovsky, M.D. as President of Leidos Biomed and Laboratory Director of the FNLCR
Leidos announces Ethan Dmitrovsky, M.D. as President of Leidos Biomed and Laboratory Director of the FNLCR

Dmitrovsky will continue the legacy of leading a team of 2,200 scientists, health professionals, and suppor...

Next Article
MHS GENESIS deployed at Madigan Army Medical Center
MHS GENESIS deployed at Madigan Army Medical Center

The Leidos Partnership for Defense Health announced the successful deployment of MHS GENESIS at Madigan Arm...